Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HS-20093 in recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors
CTR20232569Phase 2Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in head and neck squamous cell carcinoma (HNSCC), Nonhematologic neoplasms, sponsored by Hansoh Pharmaceutical Group. Started Dec 2023; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232569.